Planegg/Martinsried (pta084/12.05.2022/18:35) - The Supervisory Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer therapies, today appointed Dr Selwyn Ho as a member of the Executive Management Board and as new Chief Executive Officer (CEO) of Medigene with effect of 25 July 2022. He accepted the appointments.
As a consequence, Prof. Dolores Schendel will step down as Chief Executive Officer at the end of 24 July 2022 and fully focus on her responsibilities as Chief Scientific Officer (CSO) and Head of Research and Development at Medigene.(end)
Lochhamer Straße 11
|Contact Person:||Medigene PR/IR|
|Phone:||+49 89 2000 3333 01|
|Stock Exchanges:||regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate|